The Official Website of the Acid Maltase Deficiency Association

It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard

December 2009 Pompe Program Update

Posted on: December 04, 2009

Genzyme would like to provide an update to the US Pompe community about the status of the Alglucosidase Alfa Temporary Access Program (ATAP) and the application for Lumizyme™ (alglucosidase alfa) approval in the United States.
In a press release dated December 3, 2009, it was announced that Genzyme will reopen enrollment in ATAP to provide access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme. Enrollment in the program will be available at currently active ATAP study sites to patients who meet the eligibility criteria. Please speak to your physician about ATAP or contact Genzyme Medical Information at 800-745-4447, option 2 for more information.

To read the full Program Update, please click here.

Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.

Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA